Why the study?
Malignant pericardial effusion is a severe complication of cancer with poor survival and frequent recurrences, yet consensus on optimal local or systemic treatment is lacking.
Does intrapericardial instillation of bleomycin improve survival or prevent recurrence in patients with malignant pericardial effusions?
Does intrapericardial instillation of bleomycin improve survival or prevent recurrence in patients with malignant pericardial effusions?
Intrapericardial bleomycin instillation for malignant pericardial effusions does not appear to increase overall survival but may prevent recurrence of effusions.
Answers are grounded in this paper and cite their sources.
May reduce recurrence in malignant pericardial effusion; leaves open role pending randomized trials.
INTRODUCTION: Malignant pericardial effusion is a severe complication of lung and breast cancer. The median survival is less than 4 months and recurrences occurs in about 40% of cases. Systemic chemotherapy and/or local treatments are necessary, even if there is no consensus. METHODS: We collected data from patients in our center from 1997 to 2016 who received at least one intrapericardial instillation of bleomycin (60mg). At the same time, we conducted a review of the relevant literature on the subject. RESULTS: We included 46 patients in the analysis. Median survival was 2.6 months [95% CI: 1.7; 4.7]. Overall survival was 49% [33%; 63%] at 3 months and 28% [15%; 42%] at 6 months. In the lung cancer subgroup, overall survival was 18% [3%; 44%] at 3 months. In the breast cancer subgroup, overall survival was 73% [44%; 89%] at 3 months and 46% [21%; 69%] at 6 months. DISCUSSION: The best response rates in the literature are obtained with local instillation of bleomycin or cisplatin. Malignant pericardial effusions in breast cancer patients had a better prognosis. This is certainly related to the prognosis of the underlying disease. We have not found an increase in overall survival with intrapericardial chemotherapy injections, but preventing recurrence of malignant pericardial effusions is a benefit in itself, thus avoiding a lethal complication.
No takes yet. Share an insight, caveat, or question.
Lambert et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: